Study S002781

A Randomized, Double-Blind, Placebo-Controlled, Dose-escalation Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (PK/PD) of a Single Dose of GZR18 Injection in Obese/Overweight Subjects

ClinicalTrials.gov record

Registration

Registration: NCT06548945
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 16
Start: 2023-04-25
Primary completion: 2023-08-14
Lead sponsor: Gan and Lee Pharmaceuticals, USA
Conditions: Overweight and Obesity
Interventions: DRUG:GZR18; OTHER:Placebo
Results posted: FALSE

Registered primary outcomes

TEAE [50 days]
Anti-Drug Antibody (ADA) and Neutralizing Antibody (Nab) [50 days]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.